This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): doripenem, S-4661, Finibax (Japan)
Description: Doribax is a carbapenem antibiotic.
Carbapenems are a class of beta-lactam antibiotics with a broad spectrum of antibacterial activity, and have a structure which renders them highly resistant to beta-lactamases. Members of this class exhibit good activity against methicillin-sensitive Staphylococcus aureus, streptococci, anaerobes, enteric Gram-(-) rods (including strains that produce extended spectrum beta lactamases), Pseudomonas, and Acinetobacter. Moderate activity is observed against enterococci, and relatively modest activity against methicillin-resistant S. aureus and penicillin-resistant streptococci.
Deal Structure: On April 19, 2005, Johnson & Johnson announced that its Ortho-McNeil Pharmaceutical unit will acquire Peninsula Pharmaceuticals Inc., a privately held antibiotic developer, for $245 million in cash.
Peninsula Pharmaceuticals and Shionogi & Co. reached a licensing agreement in May 2003 for Doribax. Peninsula has obtained exclusive rights including sublicense rights to develop and market doripenem in North America; Shionogi will manufacture the product forworldwide distribution.
Partners: Shionogi & Co. Ltd.
Additional information available to subscribers only: